Zealand Pharma A/S. - ADR
ZEAL
Get informed when a big investor buys or sells
+ FollowMarket Cap$767.53M
Close$
$47.02
167.3% upside
Current Fair Value
167.3% upsideUndervalued by 167.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $767.53 Million |
|---|---|
| Enterprise Value | $-2,834,606,686.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-26.54 |
| Beta | 1.34 |
| Outstanding Shares | 43,634,412 |
Return
| Return on Equity | 15.20% |
|---|---|
| Return on Assets | 13.84% |
| Return on Invested Capital | 13.27% |
Valuation & Multiples
| P/E Ratio | 6.11 |
|---|---|
| PEG | -12.6 |
| Price to Sales | 0.17 |
| Price to Book Ratio | 0.04 |
| Enterprise Value to Revenue | 2.75 |
| Enterprise Value to EBIT | 5.21 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zealand Pharma A/S.
578 employees
CEO: Emmanuel Dulac Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ...